4.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FHTX Giù?
Forum
Previsione
Precedente Chiudi:
$4.14
Aprire:
$3.99
Volume 24 ore:
26,185
Relative Volume:
0.22
Capitalizzazione di mercato:
$231.34M
Reddito:
$34.16M
Utile/perdita netta:
$-98.43M
Rapporto P/E:
-1.7863
EPS:
-2.34
Flusso di cassa netto:
$-119.33M
1 W Prestazione:
-5.64%
1M Prestazione:
-10.68%
6M Prestazione:
-46.68%
1 anno Prestazione:
-30.45%
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Nome
Foghorn Therapeutics Inc
Settore
Industria
Telefono
617-586-3100
Indirizzo
500 TECHNOLOGY SQUARE, CAMBRIDGE
Confronta FHTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
FHTX
Foghorn Therapeutics Inc
|
4.1504 | 240.25M | 34.16M | -98.43M | -119.33M | -2.34 |
![]()
ONC
Beigene Ltd Adr
|
241.99 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
434.89 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
587.31 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
74.77 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-23 | Iniziato | Citizens JMP | Mkt Outperform |
2025-01-30 | Iniziato | B. Riley Securities | Buy |
2024-09-03 | Iniziato | Jefferies | Buy |
2024-08-19 | Iniziato | Evercore ISI | Outperform |
2023-03-28 | Iniziato | BofA Securities | Buy |
2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
2021-11-22 | Iniziato | H.C. Wainwright | Buy |
2020-11-17 | Iniziato | Cowen | Outperform |
2020-11-17 | Iniziato | Goldman | Buy |
2020-11-17 | Iniziato | Morgan Stanley | Overweight |
2020-11-17 | Iniziato | Wedbush | Outperform |
Mostra tutto
Foghorn Therapeutics Inc Borsa (FHTX) Ultime notizie
Foghorn Therapeutics Inc. to Participate in Major Upcoming Healthcare Conferences in 2025 - Nasdaq
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences - GlobeNewswire
10,895 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Acquired by Cubist Systematic Strategies LLC - Defense World
(FHTX) Trading Report - news.stocktradersdaily.com
Q2 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World
Wedbush Expects Weaker Earnings for Foghorn Therapeutics - Defense World
JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates - MSN
FHTX: JMP Securities Reiterates Market Outperform Rating for Fog - GuruFocus
FHTX: JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics | FHTX Stock News - GuruFocus
Foghorn Therapeutics Reports Q1 2025 Financial Results - TipRanks
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update - GlobeNewswire
Foghorn Therapeutics: Pioneering Precision Medicine with Innovative Pharmacology and AI Integration - TipRanks
Foghorn Therapeutics Inc. reports results for the quarter ended March 31Earnings Summary - TradingView
FHTX Exceeds Revenue Expectations and Advances Pipeline Programs - GuruFocus
Foghorn Therapeutics Advances FHD-909 Phase 1 Trial - TipRanks
Foghorn Therapeutics Inc. SEC 10-Q Report - TradingView
Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Foghorn Therapeutics Advances Cancer Drug Pipeline with Strong Financial Results: Phase 1 Trial Shows Promise - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Holdings Boosted by Wells Fargo & Company MN - Defense World
Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) PT at $12.13 - Defense World
Ted Myles Joins Cellarity as Chief Executive Officer - Stock Titan
Barclays PLC Increases Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
(FHTX) Trading Advice - news.stocktradersdaily.com
Renaissance Technologies LLC Acquires 22,500 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics’ SWOT analysis: chromatin pioneer’s stock faces clinical hurdles - Investing.com Nigeria
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference - GlobeNewswire
Foghorn Therapeutics (FHTX) Expected to Announce Quarterly Earnings on Monday - Defense World
JPMorgan Chase & Co. Purchases 45,565 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Earns Buy Rating from HC Wainwright - Defense World
Foghorn Therapeutics expands board with biotech veterans By Investing.com - Investing.com India
Foghorn Therapeutics expands board with biotech veterans - Investing.com
Foghorn Therapeutics Elects Neil Gallagher, M.D., Ph.D., and Stuart Duty to Board of Directors - Nasdaq
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire
Foghorn Therapeutics Presents New Preclinical Data on Selective - GuruFocus
Geode Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
FHTX Unveils Promising Preclinical Data at Cancer Research Confe - GuruFocus
Foghorn Therapeutics Presents Preclinical Data at AACR 2025 - TipRanks
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update | FHTX Stock News - GuruFocus
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update - The Manila Times
Foghorn Therapeutics Presents New Preclinical Data on - GlobeNewswire
Breakthrough Cancer Drug FHD-909 Shows Synergy with Leading Treatments in Lung Cancer Studies - Stock Titan
Foghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at JMP Securities - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Earns Mkt Outperform Rating from Analysts at Citizens Jmp - Defense World
This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
JMP Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Market Outperform Recommendation - Nasdaq
Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Targ - GuruFocus
Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Target | FHTX Stock News - GuruFocus
Brokerages Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Price Target at $13.17 - Defense World
Foghorn Therapeutics to Host Virtual Investor Event to Review Pi - GuruFocus
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting | FHTX Stock News - GuruFocus
Foghorn Therapeutics Inc Azioni (FHTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):